{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:32:39Z","timestamp":1792006359160,"version":"4.4.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00125-022-05815-1","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T04:03:31Z","timestamp":1666065811000},"page":"23-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Ketones: the double-edged sword of SGLT2 inhibitors?"],"prefix":"10.1007","volume":"66","author":[{"given":"Beatrice C.","family":"Lupsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Kibbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"issue":"9","key":"5815_CR1","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/DC15-0355","volume":"38","author":"G Ferrannini","year":"2015","unstructured":"Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E (2015) Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38(9):1730\u20131735. https:\/\/doi.org\/10.2337\/DC15-0355","journal-title":"Diabetes Care"},{"issue":"10","key":"5815_CR2","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/S41574-020-0392-2","volume":"16","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ (2020) Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(10):556\u2013577. https:\/\/doi.org\/10.1038\/S41574-020-0392-2","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"5815_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/DOM.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372\u2013382. https:\/\/doi.org\/10.1111\/DOM.12054","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"5815_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/J.CLINTHERA.2013.11.002","volume":"36","author":"L Ji","year":"2014","unstructured":"Ji L, Ma J, Li H et al (2014) Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 36(1):84\u2013100. https:\/\/doi.org\/10.1016\/J.CLINTHERA.2013.11.002","journal-title":"Clin Ther"},{"issue":"3","key":"5815_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","volume":"1","author":"M Roden","year":"2013","unstructured":"Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1(3):208\u2013219. https:\/\/doi.org\/10.1016\/S2213-8587(13)70084-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"5815_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJMOA1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):17\u201318. https:\/\/doi.org\/10.1056\/NEJMOA1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"5815_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMOA1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMOA1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"5815_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMOA1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMOA1812389","journal-title":"N Engl J Med"},{"issue":"21","key":"5815_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303","journal-title":"N Engl J Med"},{"issue":"22","key":"5815_CR10","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado RHM, Bonaca MP, Raz I et al (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139(22):2516\u20132527. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.039996","journal-title":"Circulation"},{"issue":"15","key":"5815_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMOA2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMOA2004967","journal-title":"N Engl J Med"},{"issue":"2","key":"5815_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/JAMACARDIO.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148\u2013158. https:\/\/doi.org\/10.1001\/JAMACARDIO.2020.4511","journal-title":"JAMA Cardiol"},{"issue":"5","key":"5815_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/EJHF.1432","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, DeMets DL, Inzucchi SE et al (2019) A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 21(5):665\u2013675. https:\/\/doi.org\/10.1002\/EJHF.1432","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"5815_CR14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMOA2022190","journal-title":"N Engl J Med"},{"issue":"16","key":"5815_CR15","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMOA2107038","journal-title":"N Engl J Med"},{"issue":"2","key":"5815_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMOA2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMOA2030183","journal-title":"N Engl J Med"},{"key":"5815_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.EJIM.2021.03.020","volume":"87","author":"Y Lu","year":"2021","unstructured":"Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J (2021) Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. Eur J Intern Med 87:20\u201328. https:\/\/doi.org\/10.1016\/J.EJIM.2021.03.020","journal-title":"Eur J Intern Med"},{"issue":"2","key":"5815_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","volume":"63","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of hyperglycaemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2):221\u2013228. https:\/\/doi.org\/10.1007\/s00125-019-05039-w","journal-title":"Diabetologia"},{"issue":"1","key":"5815_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G et al (2020) Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract 26(1):107\u2013139. https:\/\/doi.org\/10.4158\/CS-2019-0472","journal-title":"Endocr Pract"},{"issue":"2","key":"5815_CR20","doi-asserted-by":"publisher","first-page":"108101","DOI":"10.1016\/J.JDIACOMP.2021.108101","volume":"36","author":"Y Handelsman","year":"2022","unstructured":"Handelsman Y, Anderson JE, Bakris GL et al (2022) DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complicat 36(2):108101. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2021.108101","journal-title":"J Diabetes Complicat"},{"issue":"34","key":"5815_CR21","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/EURHEARTJ\/EHAB484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, MacH F, Smulders YM et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227\u20133337. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAB484","journal-title":"Eur Heart J"},{"issue":"18","key":"5815_CR22","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e876\u2013e894. https:\/\/doi.org\/10.1161\/CIR.0000000000001062","journal-title":"Circulation"},{"issue":"4","key":"5815_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334. https:\/\/doi.org\/10.1056\/nejmoa1515920","journal-title":"N Engl J Med"},{"issue":"10166","key":"5815_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet (London, England)"},{"issue":"24","key":"5815_CR25","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMOA1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMOA1811744","journal-title":"N Engl J Med"},{"issue":"15","key":"5815_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMOA2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMOA2024816","journal-title":"N Engl J Med"},{"key":"5815_CR27","unstructured":"Herrington WG, Frankel AH (2021) UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. Available from ukkidney.org\/sites\/renal.org\/files\/UKKA guideline_SGLT2i in adults with kidney disease v1 18.10.21.pdf"},{"issue":"2","key":"5815_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/DC17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D et al (2018) How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 41(2):356\u2013363. https:\/\/doi.org\/10.2337\/DC17-1096","journal-title":"Diabetes Care"},{"issue":"6","key":"5815_CR29","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1002\/EHF2.13615","volume":"8","author":"D Fitchett","year":"2021","unstructured":"Fitchett D, Inzucchi SE, Zinman B et al (2021) Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Hear Fail 8(6):4517\u20134527. https:\/\/doi.org\/10.1002\/EHF2.13615","journal-title":"ESC Hear Fail"},{"issue":"1","key":"5815_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/S13098-017-0275-4","volume":"9","author":"S Yagi","year":"2017","unstructured":"Yagi S, Hirata Y, Ise T et al (2017) Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 9(1):78. https:\/\/doi.org\/10.1186\/S13098-017-0275-4","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"5815_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/S11886-019-1165-1","volume":"21","author":"AJ Scheen","year":"2019","unstructured":"Scheen AJ (2019) Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep 21(8):70. https:\/\/doi.org\/10.1007\/S11886-019-1165-1","journal-title":"Curr Cardiol Rep"},{"issue":"3","key":"5815_CR32","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/S00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61(3):722\u2013726. https:\/\/doi.org\/10.1007\/S00125-017-4509-7","journal-title":"Diabetologia"},{"issue":"6","key":"5815_CR33","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1002\/EHF2.13645","volume":"8","author":"NK Dhingra","year":"2021","unstructured":"Dhingra NK, Mistry N, Puar P et al (2021) SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials. ESC Hear Fail 8(6):4693\u20134700. https:\/\/doi.org\/10.1002\/EHF2.13645","journal-title":"ESC Hear Fail"},{"issue":"1","key":"5815_CR34","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1152\/AJPREGU.00357.2011","volume":"302","author":"SC Thomson","year":"2012","unstructured":"Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302(1):R75\u2013R83. https:\/\/doi.org\/10.1152\/AJPREGU.00357.2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"1","key":"5815_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.KINT.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26\u201339. https:\/\/doi.org\/10.1016\/J.KINT.2017.12.027","journal-title":"Kidney Int"},{"issue":"6","key":"5815_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(sici)1520-7560(199911\/12)15:6<412::aid-dmrr72>3.0.co;2-8","volume":"15","author":"L Laffel","year":"1999","unstructured":"Laffel L (1999) Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev 15(6):412\u2013426. https:\/\/doi.org\/10.1002\/(sici)1520-7560(199911\/12)15:6<412::aid-dmrr72>3.0.co;2-8","journal-title":"Diabetes Metab Res Rev"},{"issue":"7","key":"5815_CR37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/DC16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG OUTCOME Trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39(7):1108\u20131114. https:\/\/doi.org\/10.2337\/DC16-0330","journal-title":"Diabetes Care"},{"key":"5815_CR38","doi-asserted-by":"publisher","first-page":"681513","DOI":"10.3389\/FRAGI.2021.681513","volume":"2","author":"Y Chu","year":"2021","unstructured":"Chu Y, Zhang C, Xie M (2021) Beta-hydroxybutyrate, friend or foe for stressed hearts. Front Aging 2:681513. https:\/\/doi.org\/10.3389\/FRAGI.2021.681513","journal-title":"Front Aging"},{"issue":"22","key":"5815_CR39","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","volume":"141","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Kelly DP, Margulies KB (2020) Implications of altered ketone metabolism and therapeutic ketosis in heart failure. Circulation 141(22):1800\u20131812. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045033","journal-title":"Circulation"},{"issue":"5","key":"5815_CR40","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/DB15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S et al (2016) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65(5):1190\u20131196. https:\/\/doi.org\/10.2337\/DB15-1356","journal-title":"Diabetes"},{"issue":"3","key":"5815_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/S40268-016-0137-9","volume":"16","author":"A Okamoto","year":"2016","unstructured":"Okamoto A, Yokokawa H, Sanada H, Naito T (2016) Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients. Drugs R D 16(3):255\u2013261. https:\/\/doi.org\/10.1007\/S40268-016-0137-9","journal-title":"Drugs R D"},{"issue":"5","key":"5815_CR42","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/DOM.13224","volume":"20","author":"D Polidori","year":"2018","unstructured":"Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA (2018) Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin. Diabetes Obes Metab 20(5):1321\u20131326. https:\/\/doi.org\/10.1111\/DOM.13224","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"5815_CR43","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/DOM.12881","volume":"19","author":"H Al Jobori","year":"2017","unstructured":"Al Jobori H, Daniele G, Adams J et al (2017) Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab 19(6):809\u2013813. https:\/\/doi.org\/10.1111\/DOM.12881","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"5815_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/S12933-021-01410-7","volume":"20","author":"R Pietschner","year":"2021","unstructured":"Pietschner R, Kolwelter J, Bosch A et al (2021) Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc Diabetol 20(1):219. https:\/\/doi.org\/10.1186\/S12933-021-01410-7","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"5815_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/JLA.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD (2022) SGLT2 inhibitors and ketone metabolism in heart failure. J Lipid Atheroscler 11(1):1. https:\/\/doi.org\/10.12997\/JLA.2022.11.1.1","journal-title":"J Lipid Atheroscler"},{"issue":"2","key":"5815_CR46","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/J.CMET.2016.12.022","volume":"25","author":"P Puchalska","year":"2017","unstructured":"Puchalska P, Crawford PA (2017) Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab 25(2):262. https:\/\/doi.org\/10.1016\/J.CMET.2016.12.022","journal-title":"Cell Metab"},{"issue":"2","key":"5815_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/01.RES.0000137170.41939.D9","volume":"95","author":"JS Ingwall","year":"2004","unstructured":"Ingwall JS, Weiss RG (2004) Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95(2):135\u2013145. https:\/\/doi.org\/10.1161\/01.RES.0000137170.41939.D9","journal-title":"Circ Res"},{"issue":"10","key":"5815_CR48","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/J.TEM.2021.07.006","volume":"32","author":"SR Yurista","year":"2021","unstructured":"Yurista SR, Nguyen CT, Rosenzweig A, de Boer RA, Westenbrink BD (2021) Ketone bodies for the failing heart: fuels that can fix the engine? Trends Endocrinol Metab 32(10):814\u2013826. https:\/\/doi.org\/10.1016\/J.TEM.2021.07.006","journal-title":"Trends Endocrinol Metab"},{"issue":"18","key":"5815_CR49","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","volume":"139","author":"R Nielsen","year":"2019","unstructured":"Nielsen R, M\u00f8ller N, Gormsen LC et al (2019) Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation 139(18):2129\u20132141. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036459","journal-title":"Circulation"},{"issue":"1","key":"5815_CR50","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/J.TEM.2013.09.002","volume":"25","author":"JC Newman","year":"2014","unstructured":"Newman JC, Verdin E (2014) Ketone bodies as signaling metabolites. Trends Endocrinol Metab 25(1):42\u201352. https:\/\/doi.org\/10.1016\/J.TEM.2013.09.002","journal-title":"Trends Endocrinol Metab"},{"key":"5815_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/FENDO.2011.00051","volume":"2","author":"K Ahmed","year":"2011","unstructured":"Ahmed K (2011) Biological roles and therapeutic potential of hydroxy-carboxylic acid receptors. Front Endocrinol (Lausanne) 2:51. https:\/\/doi.org\/10.3389\/FENDO.2011.00051","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5815_CR52","doi-asserted-by":"publisher","unstructured":"Qiu H, Novikov A, Vallon V (2017) Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev 33(5). https:\/\/doi.org\/10.1002\/DMRR.2886","DOI":"10.1002\/DMRR.2886"},{"issue":"29","key":"5815_CR53","doi-asserted-by":"publisher","first-page":"26649","DOI":"10.1074\/JBC.C500213200","volume":"280","author":"AKP Taggart","year":"2005","unstructured":"Taggart AKP, Kero J, Gan X et al (2005) d-\u03b2-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280(29):26649\u201326652. https:\/\/doi.org\/10.1074\/JBC.C500213200","journal-title":"J Biol Chem"},{"issue":"19","key":"5815_CR54","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1073\/PNAS.1016088108","volume":"108","author":"I Kimura","year":"2011","unstructured":"Kimura I, Inoue D, Maeda T et al (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc Natl Acad Sci U S A 108(19):8030\u20138035. https:\/\/doi.org\/10.1073\/PNAS.1016088108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5815_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/JDI.12644","volume":"8","author":"A Kashiwagi","year":"2017","unstructured":"Kashiwagi A, Maegawa H (2017) Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig 8(4):416\u2013427. https:\/\/doi.org\/10.1111\/JDI.12644","journal-title":"J Diabetes Investig"},{"issue":"2","key":"5815_CR56","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/S00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215\u2013225. https:\/\/doi.org\/10.1007\/S00125-016-4157-3","journal-title":"Diabetologia"},{"issue":"3","key":"5815_CR57","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/J.CMET.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S et al (2020) SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab 32(3):404\u2013419.e6. https:\/\/doi.org\/10.1016\/J.CMET.2020.06.020","journal-title":"Cell Metab"},{"issue":"7","key":"5815_CR58","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/DC09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7):1335\u20131343. https:\/\/doi.org\/10.2337\/DC09-9032","journal-title":"Diabetes Care"},{"issue":"5","key":"5815_CR59","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/J.1464-5491.2011.03246.X","volume":"28","author":"MW Savage","year":"2011","unstructured":"Savage MW, Dhatariya KK, Kilvert A et al (2011) Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med 28(5):508\u2013515. https:\/\/doi.org\/10.1111\/J.1464-5491.2011.03246.X","journal-title":"Diabet Med"},{"issue":"5866","key":"5815_CR60","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/BMJ.2.5866.578","volume":"2","author":"JF Munro","year":"1973","unstructured":"Munro JF, Campbell IW, McCuish AC, Duncan LJP (1973) Euglycaemic diabetic ketoacidosis. Br Med J 2(5866):578. https:\/\/doi.org\/10.1136\/BMJ.2.5866.578","journal-title":"Br Med J"},{"issue":"9","key":"5815_CR61","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/J.MAYOCP.2019.06.009","volume":"94","author":"J Macfarlane","year":"2019","unstructured":"Macfarlane J, Dhatariya K (2019) Incidence of euglycemic diabetic ketoacidosis in adults with type 1 diabetes in the United Kingdom before the widespread use of sodium glucose cotransporter 2 inhibitors. Mayo Clin Proc 94(9):1909\u20131910. https:\/\/doi.org\/10.1016\/J.MAYOCP.2019.06.009","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"5815_CR62","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4239\/WJD.V12.I5.514","volume":"12","author":"P Nasa","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A (2021) Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes 12(5):514\u2013523. https:\/\/doi.org\/10.4239\/WJD.V12.I5.514","journal-title":"World J Diabetes"},{"issue":"1","key":"5815_CR63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/AOG.0000000000000060","volume":"123","author":"BM Sibai","year":"2014","unstructured":"Sibai BM, Viteri OA (2014) Diabetic ketoacidosis in pregnancy. Obstet Gynecol 123(1):167\u2013178. https:\/\/doi.org\/10.1097\/AOG.0000000000000060","journal-title":"Obstet Gynecol"},{"issue":"9","key":"5815_CR64","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/DC15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38(9):1687\u20131693. https:\/\/doi.org\/10.2337\/DC15-0843","journal-title":"Diabetes Care"},{"issue":"6","key":"5815_CR65","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/J.JDIACOMP.2016.05.008","volume":"30","author":"BF Palmer","year":"2016","unstructured":"Palmer BF, Clegg DJ, Taylor SI, Weir MR (2016) Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complicat 30(6):1162\u20131166. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2016.05.008","journal-title":"J Diabetes Complicat"},{"issue":"23","key":"5815_CR66","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMC1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an sglt2 inhibitor. N Engl J Med 376(23):2300\u20132302. https:\/\/doi.org\/10.1056\/NEJMC1701990","journal-title":"N Engl J Med"},{"issue":"3","key":"5815_CR67","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/J.JDIACOMP.2016.11.004","volume":"31","author":"JS Kum-Nji","year":"2017","unstructured":"Kum-Nji JS, Gosmanov AR, Steinberg H, Dagogo-Jack S (2017) Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management. J Diabetes Complicat 31(3):611\u2013614. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2016.11.004","journal-title":"J Diabetes Complicat"},{"issue":"2","key":"5815_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S et al (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124(2):499\u2013508. https:\/\/doi.org\/10.1172\/JCI72227","journal-title":"J Clin Invest"},{"issue":"2","key":"5815_CR69","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G et al (2014) Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509\u2013514. https:\/\/doi.org\/10.1172\/JCI70704","journal-title":"J Clin Invest"},{"issue":"1","key":"5815_CR70","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1172\/JCI107537","volume":"53","author":"JE Liljenquist","year":"1974","unstructured":"Liljenquist JE, Bomboy JD, Lewis SB et al (1974) Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 53(1):190\u2013197. https:\/\/doi.org\/10.1172\/JCI107537","journal-title":"J Clin Invest"},{"issue":"7","key":"5815_CR71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/J.TEM.2015.05.011","volume":"26","author":"RG Kibbey","year":"2015","unstructured":"Kibbey RG (2015) SGLT-2 inhibition and glucagon: Cause for alarm? Trends Endocrinol Metab 26(7):337\u2013338. https:\/\/doi.org\/10.1016\/J.TEM.2015.05.011","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"5815_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/S13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S et al (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1(2):57\u201392. https:\/\/doi.org\/10.1007\/S13300-010-0006-4","journal-title":"Diabetes Ther"},{"issue":"5","key":"5815_CR73","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/NM.3828","volume":"21","author":"C Bonner","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V et al (2015) Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 21(5):512\u2013517. https:\/\/doi.org\/10.1038\/NM.3828","journal-title":"Nat Med"},{"key":"5815_CR74","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100:2849\u20132852. https:\/\/doi.org\/10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"5815_CR75","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/DC16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E, Baldi S, Frascerra S et al (2017) Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 40(6):771\u2013776. https:\/\/doi.org\/10.2337\/DC16-2724","journal-title":"Diabetes Care"},{"issue":"11","key":"5815_CR76","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"142","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J et al (2020) Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation 142(11):1028\u20131039. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.045691","journal-title":"Circulation"},{"issue":"6","key":"5815_CR77","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/DOM.14352","volume":"23","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Tang F et al (2021) Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. Diabetes Obes Metab 23(6):1426\u20131430. https:\/\/doi.org\/10.1111\/DOM.14352","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"5815_CR78","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/S00592-021-01686-X","volume":"58","author":"L Rao","year":"2021","unstructured":"Rao L, Ren C, Luo S, Huang C, Li X (2021) Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials. Acta Diabetol 58(7):869\u2013880. https:\/\/doi.org\/10.1007\/S00592-021-01686-X","journal-title":"Acta Diabetol"},{"issue":"8","key":"5815_CR79","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/1753-0407.12890","volume":"11","author":"K Li","year":"2019","unstructured":"Li K, Xu G (2019) Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials. J Diabetes 11(8):645\u2013655. https:\/\/doi.org\/10.1111\/1753-0407.12890","journal-title":"J Diabetes"},{"issue":"12","key":"5815_CR80","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/DC15-1730","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 38(12):2258\u20132265. https:\/\/doi.org\/10.2337\/DC15-1730","journal-title":"Diabetes Care"},{"key":"5815_CR81","doi-asserted-by":"publisher","first-page":"l1328","DOI":"10.1136\/BMJ.L1328","volume":"365","author":"G Musso","year":"2019","unstructured":"Musso G, Gambino R, Cassader M, Paschetta E (2019) Efficacy and safety of dual SGLT 1\/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 365:l1328. https:\/\/doi.org\/10.1136\/BMJ.L1328","journal-title":"BMJ"},{"issue":"1","key":"5815_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.JCJD.2021.04.006","volume":"46","author":"M Colacci","year":"2022","unstructured":"Colacci M, Fralick J, Odutayo A, Fralick M (2022) Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis. Can J Diabetes 46(1):10\u201315.e2. https:\/\/doi.org\/10.1016\/J.JCJD.2021.04.006","journal-title":"Can J Diabetes"},{"key":"5815_CR83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/J.DIABRES.2017.04.004","volume":"128","author":"Y Wang","year":"2017","unstructured":"Wang Y, Desai M, Ryan PB et al (2017) Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract 128:83\u201390. https:\/\/doi.org\/10.1016\/J.DIABRES.2017.04.004","journal-title":"Diabetes Res Clin Pract"},{"key":"5815_CR84","doi-asserted-by":"publisher","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 33(8). https:\/\/doi.org\/10.1002\/DMRR.2924","DOI":"10.1002\/DMRR.2924"},{"issue":"6","key":"5815_CR85","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22(6):753\u2013762. https:\/\/doi.org\/10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"issue":"6","key":"5815_CR86","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/DC18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42(6):1147\u20131154. https:\/\/doi.org\/10.2337\/DC18-2316","journal-title":"Diabetes Care"},{"issue":"10","key":"5815_CR87","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1111\/DOM.13811","volume":"21","author":"RM Goldenberg","year":"2019","unstructured":"Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B (2019) Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab 21(10):2192\u20132202. https:\/\/doi.org\/10.1111\/DOM.13811","journal-title":"Diabetes Obes Metab"},{"key":"5815_CR88","unstructured":"US Food and Drug Administration (2022) FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available from www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious Accessed 2 May 2022."},{"issue":"11","key":"5815_CR89","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.2337\/DC20-1244","volume":"43","author":"EJ Meyer","year":"2020","unstructured":"Meyer EJ, Mignone E, Hade A, Thiruvenkatarajan V, Bryant RV, Jesudason D (2020) Periprocedural euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitor therapy during colonoscopy. Diabetes Care 43(11):e181\u2013e184. https:\/\/doi.org\/10.2337\/DC20-1244","journal-title":"Diabetes Care"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-022-05815-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-022-05815-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T20:01:57Z","timestamp":1697572917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-022-05815-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5815"],"URL":"https:\/\/doi.org\/10.1007\/s00125-022-05815-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}